US equities |
TSLA $394.52 ▲+5.99% MU $906.88 ▲+3.34% SPCX $148.83 ▲+0.91% NVDA $215.69 ▲+2.24% META $641.85 ▼-0.12% SNDK $1,263.05 ▲+2.02% AAPL $344.40 ▼-0.95% INTC $90.92 ▲+4.55%
FinancialContent

Cocrystal Pharma, Inc. - Common Stock (NQ:COCP)

0.9800 +0.0300 (+3.16%)
Delayed Quote Updated: 12:06 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cocrystal Pharma, Inc. - Common Stock

News headline image
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for March 13th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
Via ACCESSWIRE
News headline image
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap
Via ACCESSWIRE
News headline image
Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - January 23, 2023) - The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ: COCP) ("Cocrystal," "Cocrystal... 
Via Newsfile
News headline image
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022
From Cocrystal Pharma, Inc.
Via GlobeNewswire
News headline image
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
From Cocrystal Pharma, Inc.
Via GlobeNewswire
News headline image
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
From Cocrystal Pharma, Inc.
Via GlobeNewswire
News headline image
Cocrystal Pharma to Participate in Two Investor Conferences in November
From Cocrystal Pharma, Inc.
Via GlobeNewswire
News headline image
Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza
From Cocrystal Pharma, Inc.
Via GlobeNewswire
News headline image
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
From Cocrystal Pharma, Inc.
Via GlobeNewswire
News headline image
Cocrystal Pharma to Present at the LD Micro Main Event XV
From Cocrystal Pharma, Inc.
Via GlobeNewswire
News headline image
Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022
From Cocrystal Pharma, Inc.
Via GlobeNewswire
News headline image
Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19
From Cocrystal Pharma, Inc.
Via GlobeNewswire
News headline image
Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference
From Cocrystal Pharma, Inc.
Via GlobeNewswire
News headline image
Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split
From Cocrystal Pharma, Inc.
Via GlobeNewswire
News headline image
Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - August 3, 2022) - The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ: COCP) ("the Company"),... 
Via Newsfile
New COVID-19 Vaccination Mandates Make Rapid COVID Tests More Essential Than Ever
Via FinancialNewsMedia
California and NYC Order Mandatory COVID-19 Testing Among Municipal Workers
Via FinancialNewsMedia